ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACAD shares.
View ACAD analyst ratings or view top-rated stocks.

18 equities research analysts have issued 1 year price targets for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they predict the company's share price to reach $20.44 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.

ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD stock has increased by 16.6% and is now trading at $18.57.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ACAD earnings forecast.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings data on Wednesday, November, 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. The biopharmaceutical company had revenue of $130.70 million for the quarter, compared to the consensus estimate of $139.04 million. ACADIA Pharmaceuticals had a negative net margin of 42.49% and a negative trailing twelve-month return on equity of 47.09%. The firm's quarterly revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.09) earnings per share.

ACADIA Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $510.00 million-$520.00 million, compared to the consensus revenue estimate of $530.69 million.

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.59%), Hennion & Walsh Asset Management Inc. (0.13%), Boenning & Scattergood Inc. (0.03%), Dupont Capital Management Corp (0.01%), Allspring Global Investments Holdings LLC (0.01%) and Exchange Traded Concepts LLC (0.00%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends.

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACAD stock can currently be purchased for approximately $18.57.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.01 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

The company employs 514 workers across the globe.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.